Dose predictions for [¹⁷⁷Lu]Lu-DOTA-panitumumab F(ab')₂ in NRG mice with HNSCC patient-derived tumour xenografts based on [⁶⁴Cu]Cu-DOTA-panitumumab F(ab')₂ - implications for a PET theranostic strategy.

ABSTRACT:

Background

Epidermal growth factor receptors (EGFR) are overexpressed on many head and neck squamous cell carcinoma (HNSCC). Radioimmunotherapy (RIT) with F(ab')₂ of the anti-EGFR monoclonal antibody panitumumab labeled with the β-particle emitter, ¹⁷⁷Lu may be a promising treatment for HNSCC. Our aim was to assess the feasibility of a theranostic strategy that combines positron emission tomography (PET) with [⁶⁴Cu]Cu-DOTA-panitumumab F(ab')₂ to image HNSCC and predict the radiation equivalent doses to the tumour and normal organs from RIT with [¹⁷⁷Lu]Lu-DOTA-panitumumab F(ab')₂.

Results

Panitumumab F(ab')₂ were conjugated to DOTA and complexed to ⁶⁴Cu or ¹⁷⁷Lu in high radioche

SUBMITTER: Ku A 

PROVIDER: S-EPMC8360260 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature